Trial · NCT02153632

Efficacy and Safety of Amantadine Hydrogen Chloride (HCl) ER Tablets in Parkinson's Disease Subjects With LID

NCT02153632, Phase 3, Terminated, Adamas Pharmaceuticals, Inc.; results first posted 2019-04-02

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Efficacy and Safety of Amantadine Hydrogen Chloride (HCl) ER Tablets in Parkinson's Disease Subjects With LID. Trials, record NCT02153632. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02153632

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Efficacy and Safety of Amantadine Hydrogen Chloride (HCl) ER Tablets in Parkinson's Disease Subjects With LID
NCT number: NCT02153632
Status: Terminated
Phases: Phase 3
Enrollment: 135 participants, actual
Lead sponsor: Adamas Pharmaceuticals, Inc.
Conditions: Parkinson's Disease, Levodopa Induced Dyskinesia (LID)
Interventions: amantadine HCl ER, Placebo
First posted: 2014-06-03
Last updated: 2022-02-16
Results first posted: 2019-04-02

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Unified Dyskinesia Rating Scale	Change from baseline to Day 98	The Unified Dyskinesia Rating Scale is a validated tool for assessment of dyskinesia (involuntary movements) in Parkinson's Disease patients. Rating consists of the change from baseline to Day 98 of the sum of the 26 questions comprising the questionnaire. Each question in the questionnaire is rated on a 5 point scale from 0-4 where 0 is a better outcome. Questions assess: over the past week total hours with dyskinesia and total hours without dyskinesia; problems with speech, chewing and swallowing, eating, dressing, hygiene, handwriting, hobbies, balance, socializing, emotions, spasm or cramps, pain without dystonia and pain from dystonia. The minimum (better) value is 0 and the maximum (worse) value is 130.
Secondary	Mobility State Self-Assessment - Subject Diary Cards	Day 14 and Day 98 of treatment	hange from baseline in the number of awake hours without troublesome dyskinesia (involuntary movements). Every half hour the subject will indicate in the diary if the medication has ("ON") or has not ("OFF") produced benefits in terms of mobility, slowness and rigidity. Valid diaries of the 3 consecutive days prior to each visit will be averaged with respect to the number of awake hours without troublesome dyskinesia. The change from baseline in the number of waking hours that subjects report being "ON" without troublesome dyskinesias will be analyzed at analysis visits Day 14 and Day 98 of treatment. Higher scores mean a better outcome and the maximum value is 24 hours.

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Unified Dyskinesia Rating Scale	Change from baseline to Day 98	Intent to treat population	score on a scale	MEAN
SECONDARY	Mobility State Self-Assessment - Subject Diary Cards	Day 14 and Day 98 of treatment	The number analyzed is the number of subjects with values at each time point.	Hours	MEAN

Source ClinicalTrials.gov

Results by group18

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Unified Dyskinesia Rating Scale	240mg Amantadine HCl ER Tablets	Visit 2 (Baseline)	41.3	Standard Deviation 13.91	score on a scale
Unified Dyskinesia Rating Scale	320mg Amantadine HCl ER Tablets	Visit 2 (Baseline)	36.3	Standard Deviation 12.40	score on a scale
Unified Dyskinesia Rating Scale	Placebo Tablets for Amantadine	Visit 2 (Baseline)	40.7	Standard Deviation 13.98	score on a scale
Unified Dyskinesia Rating Scale	240mg Amantadine HCl ER Tablets	Visit 7 (Day 98)/Stable Dose LOCF [1]	41.3	Standard Deviation 13.98	score on a scale
Unified Dyskinesia Rating Scale	320mg Amantadine HCl ER Tablets	Visit 7 (Day 98)/Stable Dose LOCF [1]	36.3	Standard Deviation 12.40	score on a scale
Unified Dyskinesia Rating Scale	Placebo Tablets for Amantadine	Visit 7 (Day 98)/Stable Dose LOCF [1]	40.7	Standard Deviation 13.98	score on a scale
Unified Dyskinesia Rating Scale	240mg Amantadine HCl ER Tablets	Mean Change from Baseline (SD)	-15.2	Standard Deviation 15.58	score on a scale
Unified Dyskinesia Rating Scale	320mg Amantadine HCl ER Tablets	Mean Change from Baseline (SD)	-13.7	Standard Deviation 10.95	score on a scale
Unified Dyskinesia Rating Scale	Placebo Tablets for Amantadine	Mean Change from Baseline (SD)	-9.0	Standard Deviation 10.62	score on a scale
Mobility State Self-Assessment - Subject Diary Cards	240mg Amantadine HCl ER Tablets	Visit 2 (Baseline)	10.4	Standard Deviation 3.76	Hours

1 to 10 of 18Source ClinicalTrials.gov

See all 18 results by group

Participant flow9

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	240mg Amantadine HCl ER Tablets	45
Overall Study	STARTED	320mg Amantadine HCl ER Tablets	46
Overall Study	STARTED	Placebo Tablets for Amantadine	44
Overall Study	COMPLETED	240mg Amantadine HCl ER Tablets	27
Overall Study	COMPLETED	320mg Amantadine HCl ER Tablets	27
Overall Study	COMPLETED	Placebo Tablets for Amantadine	25
Overall Study	NOT COMPLETED	240mg Amantadine HCl ER Tablets	18
Overall Study	NOT COMPLETED	320mg Amantadine HCl ER Tablets	19
Overall Study	NOT COMPLETED	Placebo Tablets for Amantadine	19

Source ClinicalTrials.gov

Adverse events513

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Anaemia	Blood and lymphatic system disorders	240mg Amantadine HCl ER Tablets	0	45	0
other	Anaemia	Blood and lymphatic system disorders	320mg Amantadine HCl ER Tablets	0	46	0
other	Anaemia	Blood and lymphatic system disorders	Placebo Tablets for Amantadine	1	44	1
other	Heart valve incompetence	Cardiac disorders	240mg Amantadine HCl ER Tablets	0	45	0
other	Heart valve incompetence	Cardiac disorders	320mg Amantadine HCl ER Tablets	1	46	1
other	Heart valve incompetence	Cardiac disorders	Placebo Tablets for Amantadine	0	44	0
other	Tachycardia	Cardiac disorders	240mg Amantadine HCl ER Tablets	0	45	0
other	Tachycardia	Cardiac disorders	320mg Amantadine HCl ER Tablets	0	46	0
other	Tachycardia	Cardiac disorders	Placebo Tablets for Amantadine	1	44	1
other	Hypoacusis	Ear and labyrinth disorders	240mg Amantadine HCl ER Tablets	0	45	0

1 to 10 of 513Source ClinicalTrials.gov

See all 513 adverse events

Adverse event totals9

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	240mg Amantadine HCl ER Tablets	0	45
Total, all-cause mortality	320mg Amantadine HCl ER Tablets	0	46
Total, all-cause mortality	Placebo Tablets for Amantadine	0	44
Total, other adverse events	240mg Amantadine HCl ER Tablets	36	45
Total, other adverse events	320mg Amantadine HCl ER Tablets	38	46
Total, other adverse events	Placebo Tablets for Amantadine	29	44
Total, serious adverse events	240mg Amantadine HCl ER Tablets	1	45
Total, serious adverse events	320mg Amantadine HCl ER Tablets	4	46
Total, serious adverse events	Placebo Tablets for Amantadine	6	44

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02153632

GET https://conductscience.org/api/trials/v1/NCT02153632/events?page=2

API reference For AI assistants